HRAS mutation as a diagnostic molecular analysis for epithelial‐myoepithelial carcinoma of the parotid gland: A case report

Abstract

Key Clinical Message HRAS mutations are frequent genetic alterations in epithelial‐myoepithelial carcinoma, and they may be useful as ancillary molecular tests and predictive molecular tests for targeted therapy with tipifarnib.

Keywords

• epithelial‐myoepithelial carcinoma
• HRAS mutation
• salivary gland carcinoma